CN115161389A - 用于危重患者的死亡预后的生物标志物 - Google Patents

用于危重患者的死亡预后的生物标志物 Download PDF

Info

Publication number
CN115161389A
CN115161389A CN202210792075.2A CN202210792075A CN115161389A CN 115161389 A CN115161389 A CN 115161389A CN 202210792075 A CN202210792075 A CN 202210792075A CN 115161389 A CN115161389 A CN 115161389A
Authority
CN
China
Prior art keywords
patient
death
biomarker
sepsis
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210792075.2A
Other languages
English (en)
Chinese (zh)
Inventor
普尔威施·卡特里
蒂莫西·E·斯威尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN115161389A publication Critical patent/CN115161389A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
CN202210792075.2A 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物 Pending CN115161389A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662354789P 2016-06-26 2016-06-26
US62/354,789 2016-06-26
CN201780039163.2A CN109451744B (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物
PCT/US2017/029468 WO2018004806A1 (en) 2016-06-26 2017-04-25 Biomarkers for use in prognosis of mortality in critically ill patients

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780039163.2A Division CN109451744B (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Publications (1)

Publication Number Publication Date
CN115161389A true CN115161389A (zh) 2022-10-11

Family

ID=60786346

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210792075.2A Pending CN115161389A (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物
CN201780039163.2A Active CN109451744B (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780039163.2A Active CN109451744B (zh) 2016-06-26 2017-04-25 用于危重患者的死亡预后的生物标志物

Country Status (7)

Country Link
US (4) US10344332B2 (cg-RX-API-DMAC7.html)
EP (1) EP3475473A4 (cg-RX-API-DMAC7.html)
JP (2) JP2019530878A (cg-RX-API-DMAC7.html)
CN (2) CN115161389A (cg-RX-API-DMAC7.html)
AU (2) AU2017289600A1 (cg-RX-API-DMAC7.html)
CA (1) CA3024724A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018004806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10344332B2 (en) * 2016-06-26 2019-07-09 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for use in prognosis of mortality in critically ill patients
WO2018140256A1 (en) 2017-01-17 2018-08-02 Duke University Gene expression signatures useful to predict or diagnose sepsis and methods of using the same
US12571044B2 (en) 2018-02-27 2026-03-10 The Board Of Trustees Of The Leland Stanford Junior University Classifier for identification of robust sepsis subtypes
WO2020198068A1 (en) * 2019-03-22 2020-10-01 Inflammatix, Inc. Systems and methods for deriving and optimizing classifiers from multiple datasets
US12263478B2 (en) 2019-04-28 2025-04-01 Visby Medical, Inc. Molecular diagnostic devices with digital detection capability and wireless connectivity
WO2021083872A1 (en) * 2019-10-28 2021-05-06 F. Hoffmann-La Roche Ag Sepsis management
CN115803461A (zh) * 2020-04-29 2023-03-14 英芙勒玛提克斯公司 确定病毒感染受试者的死亡风险
WO2022066963A1 (en) * 2020-09-25 2022-03-31 The Board Of Trustees Of The Leland Stanford Junior University Method for determining a virally-infected subject's risk of developing severe symptoms
WO2022235765A2 (en) 2021-05-04 2022-11-10 Inflammatix, Inc. Systems and methods for assessing a bacterial or viral status of a sample
CN114606308A (zh) * 2022-01-26 2022-06-10 江门市中心医院 脓毒症ards的预后与治疗标志物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
WO2013040099A2 (en) * 2011-09-12 2013-03-21 Langley Raymond Sepsis prognosis biomarkers
CN105518153A (zh) * 2013-06-20 2016-04-20 因姆内克斯普雷斯私人有限公司 生物标志物鉴定

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245615A (en) 1991-06-06 1993-09-14 International Business Machines Corporation Diagnostic system and interface for a personal computer
WO1998002836A2 (en) 1996-07-12 1998-01-22 Iliff Edwin C Computerized medical diagnostic system utilizing list-based processing
CN1829730A (zh) * 2002-11-12 2006-09-06 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20090297474A1 (en) * 2005-11-25 2009-12-03 Dermot Kelleher Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels
EP2388594A1 (en) * 2010-05-17 2011-11-23 Roche Diagnostics GmbH GDF-15 based means and methods for survival and recovery prediction in acute inflammation
US20110312521A1 (en) * 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
US20120034214A1 (en) * 2010-07-22 2012-02-09 Isis Innovation Limited Methods and kits for determining the prognosis of pulmonary sarcoidosis
KR20140044773A (ko) * 2011-01-11 2014-04-15 미쓰비시 가가쿠 메디엔스 가부시키가이샤 패혈증 예후의 예측 방법
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. 循環バイオマーカー
CA2942577A1 (en) * 2014-03-14 2015-09-17 Robert E. W. Hancock Diagnostic for sepsis
US10344332B2 (en) * 2016-06-26 2019-07-09 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for use in prognosis of mortality in critically ill patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
WO2013040099A2 (en) * 2011-09-12 2013-03-21 Langley Raymond Sepsis prognosis biomarkers
CN105518153A (zh) * 2013-06-20 2016-04-20 因姆内克斯普雷斯私人有限公司 生物标志物鉴定

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TSALIK EL等: "An integrated transcriptome and expressed variant analysis of sepsis survival and death", 《GENOME MED》, vol. 6, no. 11, 26 November 2014 (2014-11-26), pages 1 - 15, XP021207766, DOI: 10.1186/s13073-014-0111-5 *
许程,徐元宏: "脓毒症早期预警生物标志物的研究进展", 《检验医学》, vol. 30, no. 5, 31 May 2015 (2015-05-31), pages 533 - 536 *

Also Published As

Publication number Publication date
JP2019530878A (ja) 2019-10-24
CN109451744B (zh) 2022-08-05
CN109451744A (zh) 2019-03-08
AU2022211785A1 (en) 2022-08-25
JP2022153436A (ja) 2022-10-12
AU2017289600A1 (en) 2018-12-06
WO2018004806A1 (en) 2018-01-04
US10648033B2 (en) 2020-05-12
US20180274031A1 (en) 2018-09-27
US20240011096A1 (en) 2024-01-11
US11608531B2 (en) 2023-03-21
US20190106750A1 (en) 2019-04-11
CA3024724A1 (en) 2018-01-04
US10344332B2 (en) 2019-07-09
EP3475473A4 (en) 2020-01-22
US20190300959A1 (en) 2019-10-03
EP3475473A1 (en) 2019-05-01

Similar Documents

Publication Publication Date Title
CN109451744B (zh) 用于危重患者的死亡预后的生物标志物
US20220127673A1 (en) Methods for diagnosis of bacterial and viral infections
JP2023138990A (ja) 敗血症の診断法
EP3362579B1 (en) Methods for diagnosis of tuberculosis
WO2022235765A2 (en) Systems and methods for assessing a bacterial or viral status of a sample
JP2023518291A (ja) 循環遊離mRNAプロファイリングアッセイを使用してアルツハイマー病のリスクを検出するシステムおよび方法
CN118159668A (zh) 用于确定呼吸道感染风险的方法
WO2020096796A1 (en) Method for predicting severe dengue

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20221011

WD01 Invention patent application deemed withdrawn after publication